Department of Medicine, Cardiology Division, Loma Linda University School of Medicine, Loma Linda, California 92354, USA.
Clin Cardiol. 2010 Jun;33(6):345-52. doi: 10.1002/clc.20771.
Heart failure (HF) is a common condition associated with substantial cost, morbidity, and mortality. Because results of clinical trials in the acute decompensated heart failure (ADHF) setting have been mostly neutral, loop diuretics remain the mainstay of treatment.
Loop diuretic use may be associated with unfavorable outcomes.
A MEDLINE literature search was performed to identify articles relating to heart failure and loop diuretics. The current evidence on the risks and benefits of loop diuretics for the treatment of ADHF is reviewed.
Loop diuretics are associated with symptomatic improvements in congestion, urine output, and body weight, but have shown no long-term mortality benefit. Loop diuretics, especially at high doses, are associated with worsened renal function and other poor outcomes.
Loop diuretics still prove useful in HF treatment, but risk-benefit analysis of these agents in the treatment of ADHF requires a well-designed prospective study.
心力衰竭(HF)是一种常见病症,与大量的费用、发病率和死亡率有关。由于急性失代偿性心力衰竭(ADHF)治疗的临床试验结果大多为中性,因此袢利尿剂仍然是治疗的主要方法。
袢利尿剂的使用可能与不良结局有关。
对与心力衰竭和袢利尿剂相关的文献进行了 MEDLINE 文献检索。对目前关于 ADHF 治疗中袢利尿剂的风险和益处的证据进行了综述。
袢利尿剂可改善充血、尿量和体重等症状,但没有显示出长期的死亡率益处。袢利尿剂,尤其是高剂量,与肾功能恶化和其他不良结局有关。
袢利尿剂在 HF 治疗中仍然有用,但需要进行精心设计的前瞻性研究,对这些药物在 ADHF 治疗中的风险效益进行分析。